secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001493152-24-014284
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon regains Nasdaq minimum bid price compliance, deficiency resolved
-----------------------------------------------------------------------

- Nasdaq notified Imunon on April 10, 2024, that compliance with Listing Rule 5550(a)(2) was regained after 10 consecutive trading days with bid price over $1.00.
- The deficiency notice from December 26, 2023, is now fully resolved; stock maintains listing on Nasdaq Capital Market under symbol IMNN.
- Executive Chairman notes topline results from OVATION 2 Study for IMNN-001 in advanced ovarian cancer expected mid-2024.
- Company plans to begin Phase 1 study of COVID-19 booster vaccine (IMNN-101) in Q2 2024 after FDA IND clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315224014284/0001493152-24-014284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315224014284/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer